Afatinib is active in osteosarcoma in osteosarcoma cell lines.
Afatinib
/ pharmacology
Animals
Antineoplastic Agents
/ pharmacology
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Disease Models, Animal
Dose-Response Relationship, Drug
ErbB Receptors
/ genetics
Humans
Osteosarcoma
/ drug therapy
Protein Kinase Inhibitors
/ pharmacology
Receptor, ErbB-2
/ genetics
Xenograft Model Antitumor Assays
Afatinib
Antitumoral
ErbB
Osteosarcoma
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
09
02
2020
accepted:
15
04
2020
pubmed:
26
4
2020
medline:
17
6
2020
entrez:
26
4
2020
Statut:
ppublish
Résumé
Osteosarcoma is the most common bone tumor, mainly affecting adolescents and young adults, and metastatic disease has poor outcomes with a dismal overall survival. Currently, chemotherapy is the standard of care with limited results, finding that new therapies could improve these outcomes. Preclinical and clinical studies have suggested a possible important role of ErbB pathway aberrations in osteosarcoma etiology. The present study shows the effect of afatinib, an irreversible ErbB family blocker in osteosarcoma cell lines. Within a panel of human osteosarcoma cell lines, we addressed cell viability assay using afatinib at increasing concentrations. Motility was measured in wound-healing assays and invasion capacity was assessed in Transwell chamber assays. Finally, to monitor ErbB pathway modulation by afatinib and related compounds, we used Western blot analyses. Cell viability inhibition, as well as a reduction of motility and migration of osteosarcoma cell line were observed after treatment with afatinib. Likewise, in the HOS cell line, afatinib decreased phosphorylation of key components in the ErbB signaling pathway. Afatinib shows relevant antitumor effect in several osteosarcoma cell lines, as it causes a significant impact on cell viability, motility, and migration with a significant decrease in the activation of ErbB pathway activity.
Identifiants
pubmed: 32333142
doi: 10.1007/s00432-020-03220-y
pii: 10.1007/s00432-020-03220-y
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Afatinib
41UD74L59M
EGFR protein, human
EC 2.7.10.1
ERBB2 protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1693-1700Commentaires et corrections
Type : ErratumIn
Références
Allison DC, Carney SC, Ahlmann ER et al (2012) A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma. https://doi.org/10.1155/2012/704872
doi: 10.1155/2012/704872
pubmed: 22550423
pmcid: 3329715
Bacci G, Briccoli A, Rocca M et al (2003) Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 14(7):1126–1134. https://doi.org/10.1093/annonc/mdg286
doi: 10.1093/annonc/mdg286
pubmed: 12853357
Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7(7):505–516. https://doi.org/10.1038/nrm1962
doi: 10.1038/nrm1962
pubmed: 16829981
Flick DA, Gifford GE (1984) Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods 68(1–2):167–175. https://doi.org/10.1016/0022-1759(84)90147-9
doi: 10.1016/0022-1759(84)90147-9
pubmed: 6707477
Gvozdenovic A, Boro A, Born W et al (2017) A bispecific antibody targeting IGF-IR and EGFR has tumor and metastasis suppressive activity in an orthotopic xenograft osteosarcoma mouse model. Am J Cancer Res 7(7):1435–1449
pubmed: 28744395
pmcid: 5523026
Hughes DPM, Thomas DG, Giordano TJ et al (2004) Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 64(6):2047–2053. https://doi.org/10.1158/0008-5472.can-03-3096
doi: 10.1158/0008-5472.can-03-3096
pubmed: 15026342
Hughes DPM, Thomas DG, Giordano TJ et al (2006) Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr Blood Cancer 46(5):614–623. https://doi.org/10.1002/pbc.20454
doi: 10.1002/pbc.20454
pubmed: 16007579
Jullien N, Dieudonné FX, Habel N et al (2013) ErbB3 silencing reduces osteosarcoma cell proliferation and tumor growth in vivo. Gene 521(1):55–61. https://doi.org/10.1016/j.gene.2013.03.031
doi: 10.1016/j.gene.2013.03.031
pubmed: 23541807
Kager L, Zoubek A, Pötschger U et al (2003) Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21(10):2011–2018. https://doi.org/10.1200/JCO.2003.08.132
doi: 10.1200/JCO.2003.08.132
pubmed: 12743156
Kansara M, Teng MW, Smyth MJ, Thomas DM (2014) Translational biology of osteosarcoma. Nat Rev Cancer 14(11):722–735. https://doi.org/10.1038/nrc3838
doi: 10.1038/nrc3838
pubmed: 25319867
Kersting C, Gebert C, Agelopoulos K et al (2007) Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Clin Cancer Res 13(10):2998–3005. https://doi.org/10.1158/1078-0432.CCR-06-2432
doi: 10.1158/1078-0432.CCR-06-2432
pubmed: 17505002
Kubo T, Piperdi S, Rosenblum J et al (2008) Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 112(10):2119–2129. https://doi.org/10.1002/cncr.23437
doi: 10.1002/cncr.23437
pubmed: 18338812
Lee JA, Ko Y, Kim DH et al (2012) Epidermal growth factor receptor: Is it a feasible target for the treatment of Osteosarcoma? Cancer Res Treat 44(3):202–209. https://doi.org/10.4143/crt.2012.44.3.202
doi: 10.4143/crt.2012.44.3.202
pubmed: 23091447
pmcid: 3467424
Liu J, Wu J, Zhou L et al (2015) ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib. Oncotarget 6(25):21341–21352. https://doi.org/10.18632/oncotarget.4179
doi: 10.18632/oncotarget.4179
pubmed: 26050198
pmcid: 4673269
MacEwen EG, Pastor J, Kutzke J et al (2004) IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 92(1):77–91. https://doi.org/10.1002/jcb.20046
doi: 10.1002/jcb.20046
pubmed: 15095405
Machiels JPH, Haddad RI, Fayette J et al (2015) Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 16(5):583–594. https://doi.org/10.1016/S1470-2045(15)70124-5
doi: 10.1016/S1470-2045(15)70124-5
pubmed: 25892145
Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer 115(7):1531–1543. https://doi.org/10.1002/cncr.24121
doi: 10.1002/cncr.24121
pubmed: 19197972
pmcid: 2813207
Normanno N, De Luca A, Bianco C et al (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366(1):2–16. https://doi.org/10.1016/j.gene.2005.10.018
doi: 10.1016/j.gene.2005.10.018
Ottaviani G, Jaffe N (2009) The epidemiology of osteosarcoma. Cancer Treat Res 152:3–13. https://doi.org/10.1007/978-1-4419-0284-9_1
doi: 10.1007/978-1-4419-0284-9_1
pubmed: 20213383
Scotlandi K, Manara MC, Hattinger CM et al (2005) Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing’s sarcoma. Eur J Cancer 41(9):1349–1361. https://doi.org/10.1016/j.ejca.2005.03.015
doi: 10.1016/j.ejca.2005.03.015
pubmed: 15913990
Sevelda F, Mayr L, Kubista B et al (2015) EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance. J Exp Clin Cancer Res 34(1):134. https://doi.org/10.1186/s13046-015-0251-5
doi: 10.1186/s13046-015-0251-5
pubmed: 26526352
pmcid: 4630894
Solca F, Dahl G, Zoephel A et al (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343(2):342–350. https://doi.org/10.1124/jpet.112.197756
doi: 10.1124/jpet.112.197756
Soria JC, Felip E, Cobo M et al (2015) Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 16(8):897–907. https://doi.org/10.1016/S1470-2045(15)00006-6
doi: 10.1016/S1470-2045(15)00006-6
pubmed: 26156651
Wen YH, Koeppen H, Garcia R et al (2007) Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. Hum Pathol 38(8):1184–1191. https://doi.org/10.1016/j.humpath.2007.01.002
doi: 10.1016/j.humpath.2007.01.002
pubmed: 17509661
Wu PK, Chen WM, Chen CF et al (2009) Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients. Jpn J Clin Oncol 39(8):514–522. https://doi.org/10.1093/jjco/hyp057
doi: 10.1093/jjco/hyp057
pubmed: 19525290
Yang JCH, Wu YL, Schuler M et al (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16(2):141–151. https://doi.org/10.1016/S1470-2045(14)71173-8
doi: 10.1016/S1470-2045(14)71173-8
pubmed: 25589191
Young NR, Soneru C, Liu J et al (2015) Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Target Oncol 10(4):501–508. https://doi.org/10.1007/s11523-014-0353-6
doi: 10.1007/s11523-014-0353-6
pubmed: 25559287
pmcid: 4492891